Related Experiment Videos
Navigation in the mega-trials waters: reflections on the Multicenter Automatic Defibrillator Implantation Trial and
1Department of Cardiology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spain.
Insights
Evidence-based cardiology, driven by mega-trials, often lacks clinical applicability. Smaller, focused studies on ventricular arrhythmias in high-risk patients offer more practical guidance for effective patient care.
Area of Science:
- Cardiology
- Clinical Trials
- Evidence-Based Medicine
Background:
- Current cardiology practice heavily relies on mega-trials and meta-analyses for guidelines.
- Evidence-based medicine principles guide cardiovascular societies like AHA, ACC, and ESC.
- Existing evidence is not always conclusive for practical clinical decision-making.
Purpose of the Study:
- To evaluate the clinical utility of different trial sizes in cardiology.
- To highlight the limitations of large, heterogeneous trials versus smaller, focused studies.
- To identify specific patient populations with ventricular tachyarrhythmias where treatment remains unclear.
Main Methods:
- Analysis of the impact of mega-trials versus smaller trials (e.g., MADIT, AVID) on clinical decisions.
- Review of guidelines from major cardiovascular societies.
- Identification of patient subgroups with sustained ventricular tachycardia (VT) and associated risk factors.
Main Results:
- Smaller trials with well-defined, high-risk patient populations can be more clinically helpful than large, homogeneous mega-trials.
- Treatment for specific ventricular tachyarrhythmia scenarios remains uncertain.
- Key uncertain areas include VT in non-coronary artery disease patients, nonsyncopal VT with coronary artery disease and LV dysfunction, and post-MI survivors with specific risk markers.
Conclusions:
- Clinically helpful medicine may benefit more from well-designed studies in select high-risk groups.
- Further research is needed to clarify optimal treatments for complex ventricular tachyarrhythmias.
- While meta-analyses support evidence-based medicine, they may not always translate to practical clinical guidance.
Abstract:
Today, cardiology seems to be driven by mega-trials and meta-analyses. Guidelines published by scientific and professional cardiovascular societies, such as the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, follow the rules of evidence-based medicine. Such evidence is not always sufficiently conclusive to practice clinically helpful medicine. Sometimes, relatively small trials, such as the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators study, may be taken as guides for current clinical decisions and as inspiration for future investigations. Large mega-trials with a great lack of homogeneity among the recruited patients are less important for clinically helpful medicine than studies enrolling well-defined, high-risk patients. It is probably important to acknowledge that the best possible treatment for many patients with ventricular tachyarrhythmias remains obscure. Among these situations are the following: (1) sustained ventricular tachycardia (VT) in patients without coronary artery disease; (2) sustained, nonsyncopal VT in patients with coronary artery disease and left ventricular dysfunction; (3) post myocardial infarction survivors with an ejection fraction < or = 35%, frequent/complex ventricular arrhythmias, depressed heart rate variability, and inducible sustained ventricular tachyarrhythmias during electrophysiologic study. Many studies are being conducted to add light where uncertainty exists, but probably only a few will contribute to the practice of clinically helpful medicine, although some will be used to produce meta-analysis to sustain evidence-based medicine.